• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AAIPharma Services, Cambridge Major Laboratories rebrand as Alcami

AAIPharma Services, Cambridge Major Laboratories rebrand as Alcami

April 5, 2016
CenterWatch Staff

AAIPharma Services (AAI) and Cambridge Major Laboratories (CML) are now Alcami, a new brand and identity as a contract development and manufacturing organization (CDMO) with expanded capabilities and capacity.

Originally joined together in late 2013, AAI and CML combined to offer analytical testing and development services for active pharmaceutical ingredients (APIs) with oral solid and parenteral dose finished product capacity.

"Alcami" represents the combination of the legacy company names in a contemporary coined name reflective of a transformation to become a worldclass solution provider to meet the growing pipeline of new products in development within the pharmaceutical and biotech industry. Improved quality and regulatory systems as well as operational performance are driving a culture of excellence across seven sites with nearly 1,000 employees in the U.S. and Europe.

Providing an integrated offering for both drug substance and drug product at every development stage beginning with solid state chemistry and formulation development, Alcami believes they have created a robust new outsourcing offering. Alcami also recently announced significant investments in additional capabilities and capacity for oral solid dose manufacturing, and parenteral fill-finish capabilities and capacity, including additional sterile lines and lyophilization capacity available now.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing